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1. Section 3.1, page 9, Class III: No Beneﬁt, recommendation #1. The sentence now reads, “The direct thrombin
inhibitor dabigatran and the factor Xa inhibitor rivaroxaban are not recommended in patients with AF and
end-stage CKD or on dialysis because of the lack of evidence from clinical trials regarding the balance of risks
and beneﬁts.” The sentence previously read, “The direct thrombin inhibitor dabigatran and the factor Xa
inhibitor rivaroxaban are not recommended in patients with AF and end-stage CKD or on hemodialysis
because of the lack of evidence from clinical trials regarding the balance of risks and beneﬁts.”
2. Section 3.1, page 8, Table 5, Class III: No Beneﬁt, recommendation #1. The sentence now reads, “Direct
thrombin dabigatran and factor Xa inhibitor rivaroxaban are not recommended in patients with AF and
end-stage CKD or on dialysis because of a lack of evidence from clinical trials regarding the balance of risks
and beneﬁts.” The sentence previously read, “Direct thrombin dabigatran and factor Xa inhibitor rivar-
oxaban are not recommended in patients with AF and end-stage CKD or on hemodialysis because of a lack
of evidence from clinical trials regarding the balance of risks and beneﬁts.”
3. Section 4, page 10, table 7, row 1, column 4, Rivaroxaban. The text now reads, “20 mg QD with the evening
meal”. The text previously read, “20 mg HS”.
4. Section 4, page 10, table 7, row 2, column 3, Dabigatran. The text now reads, “150mg BID (CrCl>30mL/min)”.
The text previously read, “150 mg BID or 75 mg BID (CrCl >30 mL/min)”.
5. Section 4, page 10, table 7, row 2, column 4, Rivaroxaban. The text now reads, “15 mg QD with the evening
meal”. The text previously read, “15 mg HS”.
6. Section 4, page 10, table 7, row 3, column 4, Rivaroxaban. The text now reads, “15 mg QD with the evening
meal”. The text previously read, “15 mg HS”.
7. Section 4, page 10, table 7, footnote list. The footnote now reads “xDose-adjusted warfarin has been used,
but observational data on safety and efﬁcacy are conﬂicting. kModeling studies suggest that dabigatran
75 mg BID might be safe for patients with CrCl 15–30 mL/min, but this has not been validated in a pro-
spective cohort. Some countries outside the United States use 110 mg BID.” The footnote previously read
“xModeling studies suggest that dabigatran 75 mg BID might be safe for patients with CrCl 15–30 mL/min,
but this has not been validated in a prospective cohort. Some countries outside the United States use
110 mg BID. kDose-adjusted warfarin has been used, but observational data on safety and efﬁcacy are
conﬂicting.” Table symbols have been adjusted accordingly.
8. Section 4, page 10, table 7, abbreviation list. The text now reads, “.CrCl, creatinine clearance; FDA, Food
and Drug Administration; INR, international normalized ratio; and QD, once daily.” The text previously
read, “.CrCl, creatinine clearance; HS, once daily in evening with food; and INR, international normalized
ratio.”
9. Section 5.2, page 12, table 9, column 1, Amiodarone. An asterisk (*) has been inserted after “Amiodarone”.
The accompanying footnote below reads, “*Multiple dosing schemes exist for the use of amiodarone.”
10. Section 5.5, page 14, table 11, Exclude/Use With Caution, Dofetilide. Added Hypomagnesemia.
11. Section 5.5, page 14, table 11, column 4, Dofetilide. The text now reads, “Primary renal elimination
involving glomerular ﬁltration and active tubular secretion: verapamil.” The text previously read,
“Metabolized by CYP3A: verapamil.”
12. Reference Section, page 20. Reference 8 was removed and replaced with references 8a and 8b.
Now listed:
8a. Al-Khatib SM, Allen Lapointe N, Chatterjee R, et al. Treatment of Atrial Fibrillation. Comparative
Effectiveness Review 119. (Prepared by the Duke Evidence-based Practice Center under Contract No.
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2305290-2007-10066-I.) AHRQ Publication No.13-EHC095-EF. Rockville, MD: Agency for Healthcare
Research and Quality; June 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/
products/358/1559/atrial-ﬁbrillation-report-130628.pdf. Accessed August 14, 2014.
8b. Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation. Comparative Effec-
tiveness Review No. 123. (Prepared by the Duke Evidence-based Practice Center under Contract No.
290-2007-10066-I.) AHRQ Publication No. 13-EHC113-EF. Rockville, MD: Agency for Healthcare
Research and Quality; August 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/
products/352/1668/stroke-atrial-ﬁbrillation-report-130821.pdf. Accessed August 14, 2014.
Previously listed:
8. Agency for Healthcare Research and Quality. Research protocol: treatment of atrial ﬁbrillation.
Available at: http://effectivehealthcare.ahrq.gov/ehc/products/358/946/AtrialFibrillationTreatment_
AmendedProtocol_20120530.pdf. 2012. Accessed May 23, 2014.http://dx.doi.org/10.1016/j.jacc.2014.04.004CORRECTION
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1. Section 4.1, page 13, table 6, Class III: No Beneﬁt, recommendation #1. The sentence now reads, “Direct
thrombin dabigatran and factor Xa inhibitor rivaroxaban are not recommended in patients with AF and
end-stage CKD or on dialysis because of a lack of evidence from clinical trials regarding the balance of risks
and beneﬁts.” The sentence previously read, “Direct thrombin dabigatran and factor Xa inhibitor rivar-
oxaban are not recommended in patients with AF and end-stage CKD or on hemodialysis because of a lack
of evidence from clinical trials regarding the balance of risks and beneﬁts.”
2. Section 4.1, page 14, Class III: No Beneﬁt, recommendation #1. The sentence now reads, “The direct
thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban are not recommended in patients
with AF and end-stage CKD or on dialysis because of the lack of evidence from clinical trials regarding the
balance of risks and beneﬁts.” The sentence previously read, “The direct thrombin inhibitor dabigatran and
the factor Xa inhibitor rivaroxaban are not recommended in patients with AF and end-stage CKD or on
hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and beneﬁts.”
3. Section 4.1.1.1, page 15, column 2, paragraph 3. The following sentence has been deleted: “HEMORR2HAGES
includes the following variables: hepatic or renal disease, ethanol abuse, malignancy, older age, reduced
platelet count or function, rebleeding, hypertension, anemia, genetic factors, excessive fall risk, and stroke.”
4. Section 4.2.2.2, page 18, ﬁrst paragraph. The sentence now reads, “Dabigatran is the ﬁrst new oral anti-
coagulant approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and
systemic embolism in patients with nonvalvular AF, and is a direct thrombin inhibitor.” The sentence
previously read, “Dabigatran was the ﬁrst new oral anticoagulant approved by the U.S. Food and Drug
Administration (FDA) for prevention of stroke in patients with AF and is a direct thrombin inhibitor.”
5. Section 4.2.2.2, page 19, ﬁgure 5, ARISTOTLE, Event Rate. The event rate now reads, “1.60 (1.41-1.80)”. The
event rate previously read, “1.80 (1.41-1.80)”.
6. Section 4.2.2.2, page 19, column 1, paragraph 3. The sentence now reads, “.(CHADS2 score 0 to 1 in 31.8%
of subjects, 2 in 35.6%, and >2 in 32.5%).” The sentence previously read, “.(CHADS2 score 0 to 1 in 31% of
subjects, 2 in 33%, and >2 in 32%).”
